Lilly(US:LLY) 智通财经网·2025-09-25 12:06Group 1 - Eli Lilly has halted an experimental drug study aimed at preventing muscle loss in obese patients due to strategic business considerations [1] - The trial was terminated on June 10, less than a month after its initiation, while a similar study for non-diabetic obese patients remains active [1] - The experimental injection was central to Eli Lilly's strategy for addressing muscle loss in patients undergoing rapid weight loss [1] Group 2 - The terminated trial was intended to follow 180 patients with type 2 diabetes who are obese or overweight for approximately 13 months, focusing on weight loss and fat reduction [1] - Eli Lilly had previously committed around $2 billion to acquire Versanis Bio to obtain bimagrumab, which was to be used in conjunction with its blockbuster drug Zepbound [1] - In a June study, Eli Lilly indicated that bimagrumab could help patients maintain muscle mass while using Novo Nordisk's weight loss drug Wegovy [2] Group 3 - Bimagrumab works by blocking a receptor that typically regulates muscle growth, and it was previously tested by Novartis in a small study involving diabetic patients [2] - In Novartis' early research, one out of 37 patients treated with bimagrumab developed pancreatitis and was hospitalized, raising concerns about the risk of pancreatitis in diabetic patients [2]